Pneumococcal Serotype Distribution and Vaccine Coverage
Author Information
Author(s): Laura M King MPH, Kristin L Andrejko PhD, Miwako Kobayashi MD, MPH, Wei Xing MS, Adam L Cohen MD, MPH, Wesley H Self MD, MPH, J Jackson Resser MS, Cynthia G Whitney MD, MPH, Adrienne Baughman, Mai Kio, Carlos G Grijalva MD, MPH, Jessica Traenkner MPAS, Nadine Rouphael MD, MSC, Joseph A Lewnard PhD
Primary Institution: University of California, Berkeley
Hypothesis
What are the proportions of invasive pneumococcal disease (IPD) cases and pneumococcal acute respiratory infections (ARIs) caused by serotypes targeted by existing and pipeline pneumococcal vaccines?
Conclusion
The study found that coverage and preventable burdens of pneumococcal disease were lowest for PCV15 and highest for PCV31.
Supporting Evidence
- PCV15, PCV20, PCV24, PCV25, and PCV31 serotypes account for varying percentages of pneumococcal ARIs in children.
- PCV-preventable burdens encompass significant numbers of outpatient-managed ARIs and IPD cases annually.
- Coverage and preventable burdens were lowest for PCV15 and highest for PCV31.
Takeaway
This study looks at how many cases of pneumonia and ear infections in kids and adults could be prevented by new vaccines against a germ called pneumococcus.
Methodology
The study used Markov chain Monte Carlo approaches to estimate serotype distribution and proportions of pneumococcal ARIs and IPD attributable to targeted serotypes.
Potential Biases
Potential geographic variation in serotype distribution could affect the estimates.
Limitations
The study relied on data from various sources, which may not fully represent geographic variations in serotype distribution.
Participant Demographics
The study included data from children and adults in the United States.
Statistical Information
Confidence Interval
95% confidence interval: 15–17%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website